Biochemical applications of Kigelia africana (Lam.) Benth. fruit extracts in diabetes mellitus

Fagbohun, Oladapo F.; Oriyomi, Olumayowa Vincent; Adekola, Mukaila B.; Msagati, Titus A.M.

doi:10.1007/s00580-020-03179-9

Cited by 10 publications

(2 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In silico ADMET predictions revealed that except having hERG inhibition potential, the compounds 11-14 showed good predicted blood-brain, Caco, and MDCK permeability. Predicted oral absorption values were found to be high where the human serum albumin binding capacities were calculated within suitable limits [45,46].…”

Section: Resultsmentioning

confidence: 99%

The potential of 4-aryl-6-morpholino-3(2H)-pyridazinone-2-arylpiperazinylacetamide as a new scaffold for SIRT2 inhibition: in silico approach guided by pharmacophore mapping and molecular docking

et al. 2021

View full text Add to dashboard Cite

Numerous studies have demonstrated that the aberrant enzymatic activity of SIRTs has been linked to various diseases like diabetes, cancer, inflammation, cardiovascular diseases, neurodegenerative disorders and therefore, the modulation of SIRTs is of therapeutic importance. The pharmacological action of substituted pyridazinones has been broadly studied and has received much attention on account of especially their cardiovascular, anticancer, anti-inflammatory, and analgesic activity. From this point of view, we evaluated our in-house compounds bearing substituted pyridazinone skeleton for their in vitro inhibitory potency against SIRT2 and the results were supported both by the compatibility with the pharmacophore model previously developed for selective SIRT2 inhibitors and by the interaction fingerprints in hSIRT2 active site. The results revealed that 4-aryl-6-morpholino-3(2H)-pyridazinone functionalized amide scaffold showing 48% inhibition against SIRT2 may be considered as a starting point in the development of new type SIRT2 inhibitors.

show abstract

Section: Resultsmentioning

confidence: 99%

The potential of 4-aryl-6-morpholino-3(2H)-pyridazinone-2-arylpiperazinylacetamide as a new scaffold for SIRT2 inhibition: in silico approach guided by pharmacophore mapping and molecular docking

et al. 2021

View full text Add to dashboard Cite

show abstract

“…However, very few studies have highlighted the compounds responsible for the observed antidiabetic activity and bioactivity of the fruit extracts concerning their blood glucose-lowering effect. Although studies have determined the basic phytochemistry of Kigelia concerning diabetes, it has often been associated with the presence of alkaloids, iridoids, and phenolic compounds [ 9 – 11 ]. Furthermore, while some studies have demonstrated the plant extracts’ ability to enhance glucose utilization in muscle, as well as improve insulin secretion [ 12 ], there is scanty information that discusses the postprandial benefits of Kigelia extracts.…”

Section: Introductionmentioning

confidence: 99%

Kigelia africana fruit fractions inhibit in vitro alpha-glucosidase activity: a potential natural alpha-glucosidase inhibitor

Muyenga,

Bamitale,

Kibuule

et al. 2024

BMC Complement Med Ther

View full text Add to dashboard Cite

Background Diabetes affects 75% of people in low-income countries, where conventional drugs like metformin are available, but newer drugs like alpha-glucosidase inhibitors are not accessible to most Southern African patients. Aim To evaluate the α-glucosidase and α-amylase inhibitory activities of fractionated aqueous extracts of Kigelia africana fruit (KAFE) and their phytochemical fingerprints using gas chromatography-mass spectrometry (GC–MS). Materials and methods We studied K. africana fruit fractions' inhibitory effects on alpha-glucosidase and alpha-amylase using bioassay-guided fractionation, and analyzed their phytochemical profiles with GC–MS. Key findings Both the aqueous extract and ethyl acetate fraction of the aqueous extract exhibited a low dose-dependent inhibition of alpha-amylase activity (p < 0.0001). At a concentration of 500 μg/mL, the aqueous extract caused an alpha-glucosidase inhibition of 64.10 ± 2.7%, with an estimated IC50 of 193.7 μg/mL, while the ethyl acetate fraction had an inhibition of 89.82 ± 0.8% and an estimated IC50 of 10.41 μg/mL. The subfraction G, which had the highest alpha-glucosidase inhibitory activity at 85.10 ± 0.7%, had significantly lower activity than the ethyl acetate fraction. The most bioactive fraction was found to contain 11"(2-cyclopenten-1-yl) undecanoic acid, ( +)- and cyclopentane undecanoic acid as well as the indole alkaloids Akuammilan-17-ol-10-methoxy, N-nitroso-2-methyl-oxazolidine and epoxide Oxirane2.2″ -(1.4-butanediyl) bis-. Conclusion The K. africana fruit fraction demonstrated significant alpha-glucosidase inhibitory activity, while its alpha-amylase inhibitory activity was limited. This study suggests a potential natural alpha-glucosidase inhibitor and phytocompounds that could serve as leads for developing antidiabetic agents.

show abstract

Ethnobotany, pharmacology and phytochemistry of medicinal plants used for management of Diabetes mellitus in Uganda, Kenya, Tanzania and the Democratic Republic of Congo

Dangana,

Abubakar,

Shinkafi

et al. 2024

Discov Appl Sci

View full text Add to dashboard Cite

Ethnopharmacological relevance For decades, patients in East Africa have used herbal medicine as an alternative and affordable therapeutic option for the treatment of diseases such as Diabetes Mellitus (DM). As a result, the primary objective of this research was to thoroughly investigate the plants employed for treating DM in Uganda, Tanzania, Kenya, and the Democratic Republic of Congo and gather pertinent ethnopharmacological and ethnomedicinal knowledge that could be applied in the development of therapies for DM. Aim of the study The study is aimed at critically reviewing the phytochemistry, pharmacology, and toxicology of medicinal plants used for treating diabetes in East African countries, including Uganda, Tanzania, Kenya, and the Democratic Republic of Congo. Method A search for relevant articles was conducted on PubMed, ISI Web of Science, Open Theses, Google Scholar, Science Direct, and Scopus, and the identified articles were evaluated for quality, relevance, and taxonomical accuracy before undergoing review. Results The study identified 140 plant species used by local communities for the management of DM in East Africa, with decoction and infusion being the most common preparation methods. The leaves, root, and stem bark were the most frequently used parts. The in vitro and in vivo studies demonstrated the antidiabetic effect of medicinal plants such as Kigelia Africana, Hagenia abyssinica (Rosaceae), Physalis peruviana among other plants used for herbal treatment elicited via stimulation of insulin release, and gluconeogenesis. Phytochemicals present were mainly flavonoids, alkaloids, saponins, tannins, and glycosides. Conclusion The local communities in Uganda, Tanzania, Kenya and the Democratic Republic of Congo use herbal medicine for managing DM, but only a fraction of these species have scientific evidence. This necessitates additional research to establish the effectiveness, safety and potentially develop novel therapeutics for the management of DM.

show abstract

Biochemical applications of Kigelia africana (Lam.) Benth. fruit extracts in diabetes mellitus

Cited by 10 publications

References 52 publications

The potential of 4-aryl-6-morpholino-3(2H)-pyridazinone-2-arylpiperazinylacetamide as a new scaffold for SIRT2 inhibition: in silico approach guided by pharmacophore mapping and molecular docking

The potential of 4-aryl-6-morpholino-3(2H)-pyridazinone-2-arylpiperazinylacetamide as a new scaffold for SIRT2 inhibition: in silico approach guided by pharmacophore mapping and molecular docking

Kigelia africana fruit fractions inhibit in vitro alpha-glucosidase activity: a potential natural alpha-glucosidase inhibitor

Ethnobotany, pharmacology and phytochemistry of medicinal plants used for management of Diabetes mellitus in Uganda, Kenya, Tanzania and the Democratic Republic of Congo

Contact Info

Product

Resources

About